Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The tolerability of oral iron supplementation for the treatment of iron deficiency anemia is disputed. OBJECTIVE: Our aim was to quantify the odds of GI side-effects in adults related to current gold standard oral iron therapy, namely ferrous sulfate. METHODS: Systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GI side-effects that included ferrous sulfate and a comparator that was either placebo or intravenous (i.v.) iron. Random effects meta-analysis modelling was undertaken and study heterogeneity was summarised using I2 statistics. RESULTS: Forty three trials comprising 6831 adult participants were included. Twenty trials (n = 3168) had a placebo arm and twenty three trials (n = 3663) had an active comparator arm of i.v. iron. Ferrous sulfate supplementation significantly increased risk of GI side-effects versus placebo with an odds ratio (OR) of 2.32 [95% CI 1.74-3.08, p<0.0001, I2 = 53.6%] and versus i.v. iron with an OR of 3.05 [95% CI 2.07-4.48, p<0.0001, I2 = 41.6%]. Subgroup analysis in IBD patients showed a similar effect versus i.v. iron (OR = 3.14, 95% CI 1.34-7.36, p = 0.008, I2 = 0%). Likewise, subgroup analysis of pooled data from 7 RCTs in pregnant women (n = 1028) showed a statistically significant increased risk of GI side-effects for ferrous sulfate although there was marked heterogeneity in the data (OR = 3.33, 95% CI 1.19-9.28, p = 0.02, I2 = 66.1%). Meta-regression did not provide significant evidence of an association between the study OR and the iron dose. CONCLUSIONS: Our meta-analysis confirms that ferrous sulfate is associated with a significant increase in gastrointestinal-specific side-effects but does not find a relationship with dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These GI complaints cause up to 50% of oral iron receiving patients to not follow their treatment plan, meaning their IDA persists [9].”
From Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota (2021) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, it is well known that taking oral iron supplements associates with constipation [9].”
From Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota (2021) · cites this paper as [9]
In the citing paper
“Impaired gut health is a common reason for poor compliance with dietary iron supplementation regimens, even in high‐income countries. 183”
From The battle for iron in enteric infections (2020) · cites this paper as [183]
In the citing paper
“Supplements have the added advantage that they typically contain ferrous salts, which are more bioavailable than dietary iron [262], with a possible drawback of increased likelihood for gastrointestinal disturbances [263].”
From Nutritional Considerations for the Vegan Athlete (2023) · cites this paper as [263]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 2×
“Heterogeneity was assessed using the I(2) statistic and substantial heterogeneity exists when I(2)>50% [37].”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 2×
“The random-effects model proposed by DerSimonian and Laird [35] was used for the meta-analysis.”
MethodThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Daily oral iron supplementation during pregnancy
Peña-Rosas, J. P., De-Regil, L. M., Dowswell, T., & Viteri, F. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004736.pub4 · Cited by 615 · cited 5×
“In trying to capture the true incidence of GI side-effects with oral iron therapy, discrepancies between studies and limitations of study design have made overall conclusions difficult to reach [11,14,15].”
BackgroundMethodResultInfluentialUK guidelines on the management of iron deficiency in pregnancy
Pavord, S., Myers, B., Robinson, S., Allard, S., Strong, J., Oppenheimer, C., & on behalf of the British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09012.x · Cited by 606 · cited 1×
“Groups mostly at risk include those with increased iron demands, for example children and pregnant women [3,4,5], and especially those with increased iron loses, for example pre-menopausal women [6] and patients with inflammatory bowel disease (IBD) [7,8].”
BackgroundZimmermann, M. B., Chassard, C., Rohner, F., N'Goran, E. K., Nindjin, C., Dostal, A., Utzinger, J., Ghattas, H., Lacroix, C., & Hurrell, R. F. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004564 · Cited by 520 · cited 2×
“For very many years patient side-effects have been the main concern with oral iron therapy [16] but, recently, studies have consistently shown that soluble oral iron also negatively impacts the colonic microbiota, promoting the presence of potentially pathogenic bacteria at the expense of beneficial bacteria [17,18,19…”
BackgroundIron, anaemia, and inflammatory bowel diseases
Gasche, C., Lomer, M. C. E., Cavill, I., & Weiss, G. (2004) · Gut · doi:10.1136/gut.2003.035758 · Cited by 494 · cited 8×
“Subgroup analysis in IBD patients showed a similar effect versus IV iron (OR = 3.14, 95%CI 1.34-7.36, p = 0.008, I2 = 0%).”
BackgroundInfluentialDiagnosis and Management of Iron-Deficiency Anaemia
COOK, J. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.022 · Cited by 452 · cited 1×
“First-line treatment is oral therapy with ferrous iron (Fe(II)) salts [9].”
BackgroundGasche, C., Berstad, A., Befrits, R., Beglinger, C., Dignass, A., Erichsen, K., Gomollon, F., Hjortswang, H., Koutroubakis, I., Kulnigg, S., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20285 · Cited by 450 · cited 8×
“Subgroup analysis in IBD patients showed a similar effect versus IV iron (OR = 3.14, 95%CI 1.34-7.36, p = 0.008, I2 = 0%).”
BackgroundInfluentialAuerbach, M., Ballard, H., Trout, J. R., McIlwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L., & Rana, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.119 · Cited by 414
Kulnigg, S., Stoinov, S., Simanenkov, V., Dudar, L. V., Karnafel, W., Garcia, L. C., Sambuelli, A. M., D'Haens, G., & Gasche, C. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01744.x · Cited by 349
Tolerability of different oral iron supplements: a systematic review
Cancelo-Hidalgo, M. J., Castelo-Branco, C., Palacios, S., Haya-Palazuelos, J., Ciria-Recasens, M., Manasanch, J., & Pérez-Edo, L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761599 · Cited by 320 · cited 5×
“However, the meta-analysis reported herein has refined the study eligibility criteria in relation to the prior review [11].”
BackgroundResultInfluentialDiagnosis and management of iron deficiency anemia in patients with IBD
Stein, J., Hartmann, F., & Dignass, A. U. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.151 · Cited by 304 · cited 1×
“We have performed sub-group analysis for pregnant women and patients with IBD since these are two population groups at higher risk of iron deficiency anemia and for whom sufficient robust data were likely to be available [14,32,33].”
MethodDepletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis
Werner, T., Wagner, S. J., Martínez, I., Walter, J., Chang, J.-S., Clavel, T., Kisling, S., Schuemann, K., & Haller, D. (2011) · Gut · doi:10.1136/gut.2010.216929 · Cited by 299
Henry, D. H., Dahl, N. V., Auerbach, M., Tchekmedyian, S., & Laufman, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-231 · Cited by 264
Intermittent oral iron supplementation during pregnancy
Peña-Rosas, J. P., De-Regil, L. M., Gomez Malave, H., Flores-Urrutia, M. C., & Dowswell, T. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009997.pub2 · Cited by 258
Van Wyck, D. B., Martens, M. G., Seid, M. H., Baker, J. B., & Mangione, A. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000275286.03283.18 · Cited by 241
Lund, E. K., Wharf, S. G., Fairweather-Tait, S. J., & Johnson, I. T. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.2.250 · Cited by 241
Schroder, O., Mickisch, O., Seidler, U., de Weerth, A., Dignass, A. U., Herfarth, H., Reinshagen, M., Schreiber, S., Junge, U., Schrott, M., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00250.x · Cited by 232
Van Wyck, D. B., Roppolo, M., Martinez, C. O., Mazey, R. M., & Mcmurray, S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00758.x · Cited by 226
Iron therapy in iron deficiency anemia in pregnancy: Intravenous route versus oral route
Bayoumeu, F., Subiran-Buisset, C., Baka, N.-E., Legagneur, H., Monnier-Barbarino, P., & Laxenaire, M. C. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.121894 · Cited by 223 · cited 2×
“Four of the studies with modified-release ferrous sulfate [56,57,58,61] reported zero GI side-effects in the IV iron arm so these data should be interpreted with caution.”
BackgroundMethodAre we giving too much iron? Low-dose iron therapy is effective in octogenarians
Rimon, E., Kagansky, N., Kagansky, M., Mechnick, L., Mashiah, T., Namir, M., & Levy, S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.01.065 · Cited by 221 · cited 1×
“Secondly, the placebo-controlled trials were not truly blind studies as blackened stools are commonly reported with oral iron [52,53] and in none of the trials included in our meta-analysis was use of a ‘stool darkener’ reported for the placebo arm.”
BackgroundOral iron supplements for children in malaria-endemic areas
Neuberger, A., Okebe, J., Yahav, D., & Paul, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006589.pub4 · Cited by 220
Dostal, A., Chassard, C., Hilty, F. M., Zimmermann, M. B., Jaeggi, T., Rossi, S., & Lacroix, C. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.148643 · Cited by 218 · cited 1×
“Gastrointestinal symptoms most probably result from a combination of two factors: (i) free radical generation through iron-induced redox cycling in the gut lumen and at the mucosal surface which can promote inflammation [18,44,45,46] and (ii) changes to the microbiota composition or metabolism [17,18,19,47].”
BackgroundHercberg, S., Preziosi, P., & Galan, P. (2001) · Public Health Nutrition · doi:10.1079/phn2001139 · Cited by 213 · cited 1×
“Groups mostly at risk include those with increased iron demands, for example children and pregnant women [3,4,5], and especially those with increased iron loses, for example pre-menopausal women [6] and patients with inflammatory bowel disease (IBD) [7,8].”
BackgroundMakrides, M., Crowther, C. A., Gibson, R. A., Gibson, R. S., & Skeaff, C. M. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.1.145 · Cited by 213
Van Wyck, D. B., Mangione, A., Morrison, J., Hadley, P. E., Jehle, J. A., & Goodnough, L. T. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02327.x · Cited by 211
Santiago, P. (2012) · The Scientific World Journal · doi:10.1100/2012/846824 · Cited by 210 · cited 1×
“Since ferrous sulfate is the gold standard (most commonly prescribed) oral iron therapy in the UK and many other countries [10,31], our aim was to quantify the odds ratio for oral ferrous sulfate- associated gastrointestinal side-effects versus placebo or IV iron.”
BackgroundIntravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy
Al-Momen, A.-K., Al-Meshari, A., Al-Nuaim, L., Saddique, A., Abotalib, Z., Khashogji, T., & Abbas, M. (1996) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0301-2115(95)02538-3 · Cited by 199
Kortman, G. A. M., Boleij, A., Swinkels, D. W., & Tjalsma, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029968 · Cited by 195 · cited 2×
“For very many years patient side-effects have been the main concern with oral iron therapy [16] but, recently, studies have consistently shown that soluble oral iron also negatively impacts the colonic microbiota, promoting the presence of potentially pathogenic bacteria at the expense of beneficial bacteria [17,18,19…”
BackgroundVaucher, P., Druais, P.-L., Waldvogel, S., & Favrat, B. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110950 · Cited by 194 · cited 1×
“In this case, subgroup analysis of the 6 included studies that used modified-release ferrous sulfate [56,57,58,59,60,61] in fact shows an OR = 3.”
MethodSeid, M. H., Derman, R. J., Baker, J. B., Banach, W., Goldberg, C., & Rogers, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.07.046 · Cited by 190
Lindgren, S., Wikman, O., Befrits, R., Blom, H., Eriksson, A., Grännö, C., Ung, K.-A., Hjortswang, H., Lindgren, A., & Unge, P. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902839667 · Cited by 180 · cited 2×
“This leads to significant treatment failures and unnecessary follow-up investigations [11,21,22,23,24,25,26,27,28,29,30].”
BackgroundDaily iron supplementation for improving anaemia, iron status and health in menstruating women
Low, M. S. Y., Speedy, J., Styles, C. E., De-Regil, L. M., & Pasricha, S.-R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009747.pub2 · Cited by 178
Breymann, C., Gliga, F., Bejenariu, C., & Strizhova, N. (2008) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2007.10.009 · Cited by 175
Prevalence of upper gastrointestinal symptoms in the general population: a systematic review.
Heading, R. C. (1999) · PubMed · Cited by 170
Intravenous versus oral iron therapy for postpartum anaemia
Bhandal, N., & Russell, R. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01062.x · Cited by 168
A Randomized, Double-Blind Placebo-Controlled Trial of Iron in Restless Legs Syndrome
Davis, B. J., Rajput, A., Rajput, M. L., Aul, E. A., & Eichhorn, G. R. (2000) · European Neurology · doi:10.1159/000008138 · Cited by 162
Reinisch, W., Staun, M., Tandon, R. K., Altorjay, I., Thillainayagam, A. V., Gratzer, C., Nijhawan, S., & Thomsen, L. L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.335 · Cited by 153
SIDE‐EFFECTS OF ORAL IRON THERAPY A double‐blind study of different iron compounds in tablet form.
HALLBERG, L., RYTTINGER, L., & SÖLVELL, L. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb19403.x · Cited by 143 · cited 2×
“This leads to significant treatment failures and unnecessary follow-up investigations [11,21,22,23,24,25,26,27,28,29,30].”
BackgroundLuminal iron levels govern intestinal tumorigenesis after Apc loss in vivo
Radulescu, S., Brookes, M. J., Salgueiro, P., Ridgway, R. A., McGhee, E., Anderson, K., Ford, S. J., Stones, D. H., Iqbal, T. H., Tselepis, C., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.003 · Cited by 130 · cited 1×
“Most recently there have been concerns over ‘available’ iron in the colon as a risk factor for inflammatory signalling and colorectal carcinogenesis [18,20].”
BackgroundCharytan, C., Qunibi, W. Y., & Bailie, G. R. (2005) · Nephron Clinical Practice · doi:10.1159/000085049 · Cited by 129
A Randomized Controlled Trial of Oral versus Intravenous Iron in Chronic Kidney Disease
Agarwal, R., Rizkala, A. R., Bastani, B., Kaskas, M. O., Leehey, D. J., & Besarab, A. (2006) · American Journal of Nephrology · doi:10.1159/000096174 · Cited by 127
Compliance to iron supplementation during pregnancy
Habib, F., Habib Zein Alabdin, E., Alenazy, M., & Nooh, R. (2009) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610902984961 · Cited by 117 · cited 2×
“This leads to significant treatment failures and unnecessary follow-up investigations [11,21,22,23,24,25,26,27,28,29,30].”
BackgroundKoloski, N. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00052-2 · Cited by 112 · cited 1×
“In order to minimize side-effect reporting bias, we have only included controlled trials with a comparator arm that included an intervention, either placebo or intravenous iron, since gastrointestinal symptoms are common even in the general population and are known to be influenced by psychological factors [48,49,50,5…”
MethodCarrier, J. C., Aghdassi, E., Cullen, J., & Allard, J. P. (2002) · Journal of Nutrition · doi:10.1093/jn/131.10.3146 · Cited by 111 · cited 1×
“Gastrointestinal symptoms most probably result from a combination of two factors: (i) free radical generation through iron-induced redox cycling in the gut lumen and at the mucosal surface which can promote inflammation [18,44,45,46] and (ii) changes to the microbiota composition or metabolism [17,18,19,47].”
BackgroundOral iron supplementation for preventing or treating anaemia among children in malaria-endemic areas
Ojukwu, J. U., Okebe, J. U., Yahav, D., & Paul, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006589.pub2 · Cited by 104 · cited 1×
“Gastrointestinal side-effects are the most commonly reported adverse effects associated with oral iron treatment and include nausea, flatulence, abdominal pain, diarrhoea, constipation, and black or tarry stools [11,12,13,14,15].”
BackgroundPrevention of Iron Deficiency Anemia in Adolescent and Adult Pregnancies
Meier, P. R., Nickerson, H. J., Olson, K. A., Berg, R. L., & Meyer, J. A. (2003) · Clinical Medicine & Research · doi:10.3121/cmr.1.1.29 · Cited by 99
Oral iron supplements for children in malaria-endemic areas
Okebe, J. U., Yahav, D., Shbita, R., & Paul, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006589.pub3 · Cited by 82 · cited 1×
“Gastrointestinal side-effects are the most commonly reported adverse effects associated with oral iron treatment and include nausea, flatulence, abdominal pain, diarrhoea, constipation, and black or tarry stools [11,12,13,14,15].”
BackgroundGastric delivery system for iron supplementation
Cook, J. D., Carriaga, M. T., SKIKNE, B. S., Kahn, S. G., & Schalch, W. (1990) · The Lancet · doi:10.1016/0140-6736(90)91135-w · Cited by 79
Pieracci, F. M., Henderson, P., Rodney, J. R. M., Holena, D. N., Genisca, A., Ip, I., Benkert, S., Hydo, L. J., Eachempati, S. R., Shou, J., et al. (2009) · Surgical Infections · doi:10.1089/sur.2008.043 · Cited by 77 · cited 1×
“One study was excluded from the final meta-analysis because it was conducted in critically ill surgical patients in intensive care so ferrous sulfate was mixed in the enteral feed rather than being delivered in pure supplemental form as in the other studies [39].”
ResultKochhar, P. K., Kaundal, A., & Ghosh, P. (2013) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2012.01982.x · Cited by 74
Saha, L., Pandhi, P., Gopalan, S., Malhotra, S., & Saha, P. K. (2007) · PubMed Central · Cited by 73
Waldvogel, S., Pedrazzini, B., Vaucher, P., Bize, R., Cornuz, J., Tissot, J.-D., & Favrat, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-8 · Cited by 71 · cited 1×
“In this case, subgroup analysis of the 6 included studies that used modified-release ferrous sulfate [56,57,58,59,60,61] in fact shows an OR = 3.”
MethodIron prophylaxis in pregnancy: Intravenous route versus oral route
Bencaiova, G. A., von Mandach, U., & Zimmermann, R. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.03.006 · Cited by 70 · cited 2×
“Four of the studies with modified-release ferrous sulfate [56,57,58,61] reported zero GI side-effects in the IV iron arm so these data should be interpreted with caution.”
BackgroundMethodSouza, A. I. D., Batista Filho, M., Bresani, C. C., Ferreira, L. O. C., & Figueiroa, J. N. (2009) · Cadernos de Saúde Pública · doi:10.1590/s0102-311x2009000600005 · Cited by 61 · cited 4×
“To support the double-blind design in future placebo-controlled clinical trials investigating gastrointestinal symptoms with oral iron it would be preferable to use a stool darkener It is generally considered that (i) doses 50–60 mg iron/day generate less side-effects than higher doses and that (ii) iron given in cont…”
BackgroundMethodInfluentialMudge, D. W., Tan, K., Miles, R., Johnson, D. W., Badve, S. V., Campbell, S. B., Isbel, N. M., van Eps, C. L., & Hawley, C. M. (2012) · Transplantation · doi:10.1097/tp.0b013e318248375a · Cited by 59
Pereira, D. I., Couto Irving, S. S., Lomer, M. C., & Powell, J. J. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-103 · Cited by 59
Self-citationSutton, P. M., Cresswell, T. R., Livesey, J. P., Speed, K., & Bagga, T. (2004) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.86b1.13936 · Cited by 56 · cited 1×
“6) with placebo [41].”
Intermittent oral iron supplementation during pregnancy
Peña-Rosas, J. P., De-Regil, L. M., Dowswell, T., & Viteri, F. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009997 · Cited by 54
Tolerability of iron: a comparison of bis-glycino iron II and ferrous sulfate.
Coplin, M., Schuette, S. A., Leichtmann, G. A., & Lashner, B. A. (1991) · PubMed · Cited by 45
Carbonyl iron for short‐term supplementation in female blood donors
Gordeuk, V. R., Brittenham, G. M., Hughes, M. A., & Keating, L. J. (1987) · Transfusion · doi:10.1046/j.1537-2995.1987.27187121482.x · Cited by 45
Verouti, S. N., Boscardin, E., Hümmler, E., & Frateschi, S. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.012 · Cited by 44
US prevalence of upper gastrointestinal symptoms: a systematic literature review.
Sobieraj, D. M., Coleman, S. M., & Coleman, C. I. (2011) · PubMed · Cited by 40
Tuomainen, T., Nyyssönen, K., Porkkala-Sarataho, E., Salonen, R. M., Baumgartner, J. A., Geisser, P., & Salonen, J. T. (1999) · Nutrition Research · doi:10.1016/s0271-5317(99)00073-1 · Cited by 39
Short‐term ferrous sulfate supplementation in female blood donors
Maghsudlu, M., Nasizadeh, S., Toogeh, G., Zandieh, T., Parandoush, S., & Rezayani, M. (2008) · Transfusion · doi:10.1111/j.1537-2995.2007.01671.x · Cited by 33
Ahn, E., Pairaudeau, N., Pairaudeau, N., Cérat, Y., Couturier, B., Fortier, A., Paradis, É., & Koren, G. (2006) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-6-10 · Cited by 31
Liguori, L. (1993) · PubMed · Cited by 31
The therapeutic equivalence of oral and intravenous iron in renal dialysis patients.
Strickland, I. D., de Saintonge, D. M. C., Boulton, F. E., Francis, B., Roubikova, J., & Waters, J. (1977) · PubMed · Cited by 28
Zaïm, M., Piselli, L., Fioravanti, P., & Kanony-Truc, C. (2011) · European Journal of Nutrition · doi:10.1007/s00394-011-0210-7 · Cited by 27 · cited 3×
“In pregnancy, adherence with ferrous sulfate has been reported as only 70–90% due to adverse-effects [27,28,43].”
BackgroundAbdullah, K., Kendzerska, T., Shah, P. S., Uleryk, E. M., & Parkin, P. C. (2012) · Public Health Nutrition · doi:10.1017/s1368980012003709 · Cited by 27 · cited 1×
“Groups mostly at risk include those with increased iron demands, for example children and pregnant women [3,4,5], and especially those with increased iron loses, for example pre-menopausal women [6] and patients with inflammatory bowel disease (IBD) [7,8].”
BackgroundOrozco, M., Solomons, N. W., Schümann, K., Friel, J. K., & de Montenegro, A. L. M. (2010) · Journal of Nutrition · doi:10.3945/jn.109.111104 · Cited by 25 · cited 1×
“Gastrointestinal symptoms most probably result from a combination of two factors: (i) free radical generation through iron-induced redox cycling in the gut lumen and at the mucosal surface which can promote inflammation [18,44,45,46] and (ii) changes to the microbiota composition or metabolism [17,18,19,47].”
BackgroundThe Factors That Affect Milk-to-Serum Ratio for Iron During Early Lactation
Yalçn, S. S., Baykan, A., Yurdakök, K., Yalçn, S., & Gücüş, A. İ. (2009) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31819146c2 · Cited by 23
Baykan, A., Yalçın, S. S., & Yurdakök, K. (2006) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2006.2650 · Cited by 22
Gasché, C., Evstatiev, R., Haas, T., Kaser, A., Knoflach, P., Petritsch, W., Weiss, G., & Reinisch, W. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273324 · Cited by 17
Clinical inquiries. Are any oral iron formulations better tolerated than ferrous sulfate?
McDiarmid, T., & Johnson, E. D. (2002) · PubMed · Cited by 16
Ganzoni, A. M., Töndury, G., & Rhyner, K. (1974) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1107912 · Cited by 13
Portincasa, P., Maggipinto, A., Berardino, M., Bonfrate, L., Costin, S., Todarello, O., Palasciano, G., Wang, D. Q. ‐., & Dumitrascu, D. L. (2009) · PubMed · Cited by 12
Mirrezaei, S. A., Parsi, R., Jahromi, S. A. T., & Askarian, M. (2008) · Iranian journal of medical sciences · Cited by 8
Fouad, G. T., Evans, M., Sharma, P., Baisley, J. E., Crowley, D. C., & Guthrie, N. (2013) · Journal of Dietary Supplements · doi:10.3109/19390211.2012.758217 · Cited by 7
Prevalence of anaemia in an inner city primary school population
Adamson, E. A., Bailey, G., Richards, N., & Wilson, H. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.116301 · Cited by 6 · cited 3×
“7 million people every year [1,2].”
InfluentialLevy, F., Andersen, P., & Ekren, T. (1978) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1978.tb08444.x · Cited by 5
Merino, S. G., Picado, A. L., Hernández, H., Mesa, J. M. M., Lasa, I. L., & Barandiarán, F. A. (2011) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2011.03.008 · Cited by 4
Side effects of alternative iron supplementation: a pilot study.
Jl, R., & Lc, P. (1998) · PubMed · Cited by 3
Research works printed but not linked: 5
- Hallberg L, Ryttinger L, Solvell L (1966) Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta medica Scandinavica Supplementum 180: 3– 10. 5957969 · DOI · Paper page
- Langstaff R, Geisser P, Heil W, Bowdler J (1993) Treatment of iron-deficiency anaemia: A lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. Br J Clin Res 4: 191– 198.
- Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, et al (2009) Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 44: 838– 845. 10.1080/00365520902839667 19330567 · DOI · Paper page
- Saha L, Pandhi P, Gopalan S, Malhotra S, Saha P (2007) Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women. MedGenMed: Medscape general medicine 9: 1 17435611 PMC1924983
- Vazquez Pacheco J (1980) A comparative study of i.v. iron dextran and an oral combination of ferrous sulfate, cyanocobalamin and folic acid in obstetrical patients. Investigacion Medica International 7: 129– 135.
Cited by
Pasricha, S.-R., Tye-Din, J., Muckenthaler, M. U., & Swinkels, D. W. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32594-0 · Cited by 1,069
Camaschella, C. (2019) · Blood · doi:10.1182/blood-2018-05-815944 · Cited by 702
Stoffel, N. U., Cercamondi, C. I., Brittenham, G., Zeder, C., Geurts-Moespot, A. J., Swinkels, D. W., Moretti, D., & Zimmermann, M. B. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30182-5 · Cited by 435
Iron deficiency anaemia: pathophysiology, assessment, practical management
Kumar, A., Sharma, E., Marley, A., Samaan, M. A., & Brookes, M. J. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000759 · Cited by 344
Lee, T., Clavel, T., Smirnov, K., Schmidt, A., Lagkouvardos, I., Walker, A., Lucio, M., Michalke, B., Schmitt-Kopplin, P., Fedorak, R., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309940 · Cited by 324
Metadata
- Authors
- Tolkien, Z., Stecher, L., Mander, A. P., Pereira, D. I. A., & Powell, J. J.
- Affiliations
- MRC Elsie Widdowson Laboratory (GB)
- MRC Biostatistics Unit (GB)
- Corresponding author
- Pereira, Dora I. A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-02-20
- Volume
- 10
- Issue
- 2
- Pages
- e0117383
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4336293
- OpenAlex
- W2049123117
- Cited by
- 833
- References
- 86
- Citations by year
- 2026: 117 · 2025: 90 · 2024: 91 · 2023: 101 · 2022: 98 · 2021: 75 · 2020: 80 · 2019: 58 · 2018: 44 · 2017: 41 · 2016: 26 · 2015: 11
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- UNICEF
- Medical Research Council (U105960399, G0800860)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- ferrous sulfate, oral iron supplementation, gastrointestinal adverse effects, iron deficiency anemia, intravenous iron, tolerability, inflammatory bowel disease, pregnancy, iron dosage
- MeSH terms
- Clinical Trials as Topic, Ferrous Compounds, Gastrointestinal Diseases, Humans, Placebo Effect, Odds Ratio, Databases, Factual, Anemia, Iron-Deficiency, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.